TrialClinical drug investigation2019

Pharmacokinetics, Safety and Tolerability of Chiglitazar, A Novel Peroxisome Proliferator-Activated Receptor (PPAR) Pan-Agonist, in Healthy Chinese Volunteers: A Phase I Study.

Hong-Rong Xu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.